Skip to main content
Top
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Development and validation of a simple questionnaire for the identification of hereditary breast cancer in primary care

Authors: Patricia Ashton-Prolla, Juliana Giacomazzi, Aishameriane V Schmidt, Fernanda L Roth, Edenir I Palmero, Luciane Kalakun, Ernestina S Aguiar, Susana M Moreira, Erica Batassini, Vanessa Belo-Reyes, Lavinia Schuler-Faccini, Roberto Giugliani, Maira Caleffi, Suzi Alves Camey

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Breast cancer is a significant public health problem worldwide and the development of tools to identify individuals at-risk for hereditary breast cancer syndromes, where specific interventions can be proposed to reduce risk, has become increasingly relevant. A previous study in Southern Brazil has shown that a family history suggestive of these syndromes may be prevalent at the primary care level. Development of a simple and sensitive instrument, easily applicable in primary care units, would be particularly helpful in underserved communities in which identification and referral of high-risk individuals is difficult.

Methods

A simple 7-question instrument about family history of breast, ovarian and colorectal cancer, FHS-7, was developed to screen for individuals with an increased risk for hereditary breast cancer syndromes. FHS-7 was applied to 9218 women during routine visits to primary care units in Southern Brazil. Two consecutive samples of 885 women and 910 women who answered positively to at least one question and negatively to all questions were included, respectively. The sensitivity, specificity and positive and negative predictive values were determined.

Results

Of the 885 women reporting a positive family history, 211 (23.8%; CI95%: 21.5–26.2) had a pedigree suggestive of a hereditary breast and/or breast and colorectal cancer syndrome. Using as cut point one positive answer, the sensitivity and specificity of the instrument were 87.6% and 56.4%, respectively. Concordance between answers in two different applications was given by a intra-class correlation (ICC) of 0.84 for at least one positive answer. Temporal stability of the instrument was adequate (ICC = 0.65).

Conclusion

A simple instrument for the identification of the most common hereditary breast cancer syndrome phenotypes, showing good specificity and temporal stability was developed and could be used as a screening tool in primary care to refer at-risk individuals for genetic evaluations.
Appendix
Available only for authorised users
Literature
3.
go back to reference Tavassoli FA, Devilee P, (Eds.): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. 2003, IARC Press: IARC Press: Lyon Tavassoli FA, Devilee P, (Eds.): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. 2003, IARC Press: IARC Press: Lyon
5.
go back to reference Cadaval Gonçalves AT, Costa Jobim PF, Vanacor R, et al: Increase in breast cancer mortality in Southern Brazil from 1980 to 2002. Cad Saúde Pública. 2007, 23: 1785-1790.CrossRefPubMed Cadaval Gonçalves AT, Costa Jobim PF, Vanacor R, et al: Increase in breast cancer mortality in Southern Brazil from 1980 to 2002. Cad Saúde Pública. 2007, 23: 1785-1790.CrossRefPubMed
6.
go back to reference Hall IJ, Burke W, Coughlin , et al: Population-Based Estimates of the Prevalence of Family History of Cancer Among Women. Community Genet. 2001, 4: 134-142. 10.1159/000051173.PubMed Hall IJ, Burke W, Coughlin , et al: Population-Based Estimates of the Prevalence of Family History of Cancer Among Women. Community Genet. 2001, 4: 134-142. 10.1159/000051173.PubMed
7.
go back to reference Eberl MD, Sunga A, Farrel C, et al: Patients with a family history of cancer: identification and management. J Am Board Fam Medicine. 2005, 18: 211-217. 10.3122/jabfm.18.3.211.CrossRef Eberl MD, Sunga A, Farrel C, et al: Patients with a family history of cancer: identification and management. J Am Board Fam Medicine. 2005, 18: 211-217. 10.3122/jabfm.18.3.211.CrossRef
8.
go back to reference Da Costa EC, Vargas FR, Moreira AS, et al: Founder effect of the BRCA1 5382insC mutation in Brazilian patients with hereditary breast ovary cancer syndrome. Cancer Genet Cytogenet. 2008, 184: 62-6. 10.1016/j.cancergencyto.2008.03.011.CrossRefPubMed Da Costa EC, Vargas FR, Moreira AS, et al: Founder effect of the BRCA1 5382insC mutation in Brazilian patients with hereditary breast ovary cancer syndrome. Cancer Genet Cytogenet. 2008, 184: 62-6. 10.1016/j.cancergencyto.2008.03.011.CrossRefPubMed
9.
go back to reference Garber JE, Offit K: Hereditary cancer predisposition syndromes. J Clin Oncol. 2005, 23: 276-292. 10.1200/JCO.2005.10.042.CrossRefPubMed Garber JE, Offit K: Hereditary cancer predisposition syndromes. J Clin Oncol. 2005, 23: 276-292. 10.1200/JCO.2005.10.042.CrossRefPubMed
11.
go back to reference Nelson HD, Huffman LH, Fu R, et al: U.S. Preventive Services Task Force Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force. Ann Intern Med. 2005, 143: 362-379.CrossRefPubMed Nelson HD, Huffman LH, Fu R, et al: U.S. Preventive Services Task Force Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force. Ann Intern Med. 2005, 143: 362-379.CrossRefPubMed
12.
go back to reference Li FP, Fraumeni JF, Mulvihill JJ, et al: A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988, 48: 5358-5362.PubMed Li FP, Fraumeni JF, Mulvihill JJ, et al: A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988, 48: 5358-5362.PubMed
13.
go back to reference Birch JM, Hartley AL, Tricker KJ, et al: Prevalence and diversity of constitutional mutations in the p53 gene among Li-Fraumeni families. Cancer Res. 1994, 54: 1298-1304.PubMed Birch JM, Hartley AL, Tricker KJ, et al: Prevalence and diversity of constitutional mutations in the p53 gene among Li-Fraumeni families. Cancer Res. 1994, 54: 1298-1304.PubMed
14.
go back to reference Eeles RA: Germline mutations in the TP53 gene. Cancer Surv. 1995, 25: 101-124.PubMed Eeles RA: Germline mutations in the TP53 gene. Cancer Surv. 1995, 25: 101-124.PubMed
15.
go back to reference Meijers-Heijboer H, Wijnen J, Vasen H, et al: The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Gen. 2003, 72: 1308-1314. 10.1086/375121.CrossRef Meijers-Heijboer H, Wijnen J, Vasen H, et al: The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Gen. 2003, 72: 1308-1314. 10.1086/375121.CrossRef
16.
go back to reference Vahteristo P, Bartkova J, Eerola H, et al: A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 2002, 71: 432-438. 10.1086/341943.CrossRefPubMedPubMedCentral Vahteristo P, Bartkova J, Eerola H, et al: A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 2002, 71: 432-438. 10.1086/341943.CrossRefPubMedPubMedCentral
18.
go back to reference Allen HJ, Briceno CA, Piver MS: Assessment of family cancer history collection and utilization in patient care. Community Genet. 1998, 1: 237-242. 10.1159/000016169.PubMed Allen HJ, Briceno CA, Piver MS: Assessment of family cancer history collection and utilization in patient care. Community Genet. 1998, 1: 237-242. 10.1159/000016169.PubMed
19.
go back to reference Murff HJ, Byrne D, Syngal S: Cancer Risk Assessment: Quality and Impact of the Family History Interview. Am J Prev Medicine. 2004, 27: 239-245. Murff HJ, Byrne D, Syngal S: Cancer Risk Assessment: Quality and Impact of the Family History Interview. Am J Prev Medicine. 2004, 27: 239-245.
20.
go back to reference Offit K, Groeger E, Turner S, et al: The "duty to warn" a patient's family members about hereditary disease risks. JAMA. 2004, 292: 1469-1473. 10.1001/jama.292.12.1469.CrossRefPubMed Offit K, Groeger E, Turner S, et al: The "duty to warn" a patient's family members about hereditary disease risks. JAMA. 2004, 292: 1469-1473. 10.1001/jama.292.12.1469.CrossRefPubMed
21.
go back to reference Roth FL, Camey SA, Caleffi M, et al: Consistency of self-reported first-degree family history of cancer: a population-based study. Familial Cancer. 2009, Roth FL, Camey SA, Caleffi M, et al: Consistency of self-reported first-degree family history of cancer: a population-based study. Familial Cancer. 2009,
22.
go back to reference Ramsey SD, Yoon P, Moonesinghe , et al: Population-based study of the prevalence of family history of cancer: Implications for cancer screening and prevention. Genet Med. 2006, 8: 571-575.CrossRefPubMedPubMedCentral Ramsey SD, Yoon P, Moonesinghe , et al: Population-based study of the prevalence of family history of cancer: Implications for cancer screening and prevention. Genet Med. 2006, 8: 571-575.CrossRefPubMedPubMedCentral
23.
go back to reference Katapodi MC, Aouizerat BE: Do women in the community recognize hereditary and sporadic breast cancer risk factors?. Oncol Nurs Forum. 2005, 32: 617-623. 10.1188/05.ONF.617-623.CrossRefPubMed Katapodi MC, Aouizerat BE: Do women in the community recognize hereditary and sporadic breast cancer risk factors?. Oncol Nurs Forum. 2005, 32: 617-623. 10.1188/05.ONF.617-623.CrossRefPubMed
24.
go back to reference Palmero EI, Ashton-Prolla P, da Rocha JC, et al: Clinical characterization and risk profile of individuals seeking genetic counseling for hereditary breast cancer in Brazil. J Genet Couns. 2007, 16: 363-371. 10.1007/s10897-006-9073-0.CrossRefPubMed Palmero EI, Ashton-Prolla P, da Rocha JC, et al: Clinical characterization and risk profile of individuals seeking genetic counseling for hereditary breast cancer in Brazil. J Genet Couns. 2007, 16: 363-371. 10.1007/s10897-006-9073-0.CrossRefPubMed
25.
go back to reference Daly MB, Stearmen B, Masny A, et al: How to establish a high-risk cancer genetics clinic: limitations and successes. Curr Oncol Rep. 2005, 7: 469-474. 10.1007/s11912-005-0012-2.CrossRefPubMed Daly MB, Stearmen B, Masny A, et al: How to establish a high-risk cancer genetics clinic: limitations and successes. Curr Oncol Rep. 2005, 7: 469-474. 10.1007/s11912-005-0012-2.CrossRefPubMed
26.
go back to reference Caleffi M, Ribeiro RA, Duarte Filho DL, et al: A model to optimize public health care and downstage breast cancer in limited-resource populations in southern Brazil. (Porto Alegre Breast Health Intervention Cohort). BMC Public Health. 2009, 9: 83-10.1186/1471-2458-9-83.CrossRefPubMedPubMedCentral Caleffi M, Ribeiro RA, Duarte Filho DL, et al: A model to optimize public health care and downstage breast cancer in limited-resource populations in southern Brazil. (Porto Alegre Breast Health Intervention Cohort). BMC Public Health. 2009, 9: 83-10.1186/1471-2458-9-83.CrossRefPubMedPubMedCentral
27.
go back to reference Palmero EI, Caleffi M, Schüler-Faccini L, et al: Population prevalence of hereditary breast cancer phenotypes and implementation of a genetic cancer risk assessment program in Southern Brazil. Accepted in Genetics and Molecular Biology. 2009, 32: Palmero EI, Caleffi M, Schüler-Faccini L, et al: Population prevalence of hereditary breast cancer phenotypes and implementation of a genetic cancer risk assessment program in Southern Brazil. Accepted in Genetics and Molecular Biology. 2009, 32:
28.
go back to reference Ramalho AS, Silva RB: Community genetics: a new discipline and its application in Brazil. Cad Saude Publica. 2000, 16: 261-263. 10.1590/S0102-311X2000000100029.CrossRefPubMed Ramalho AS, Silva RB: Community genetics: a new discipline and its application in Brazil. Cad Saude Publica. 2000, 16: 261-263. 10.1590/S0102-311X2000000100029.CrossRefPubMed
29.
go back to reference Ministério da Saúde, Brasil. Secretaria de Assistência à Saúde. Instituto Nacional do Câncer: Câncer no Brasil: Dados dos Registros de Base Populacional. Rio de Janeiro. 2003, 125- Ministério da Saúde, Brasil. Secretaria de Assistência à Saúde. Instituto Nacional do Câncer: Câncer no Brasil: Dados dos Registros de Base Populacional. Rio de Janeiro. 2003, 125-
30.
go back to reference Harzheim E, Duncan BB, Stein AT, et al: Quality and effectiveness of different approaches to primary care delivery in Brazil. BMC Health Serv Res. 2006, 6: 156-10.1186/1472-6963-6-156.CrossRefPubMedPubMedCentral Harzheim E, Duncan BB, Stein AT, et al: Quality and effectiveness of different approaches to primary care delivery in Brazil. BMC Health Serv Res. 2006, 6: 156-10.1186/1472-6963-6-156.CrossRefPubMedPubMedCentral
31.
go back to reference Gail MH, Brinton LA, Byar DP, et al: Projecting individualized probabilities of developing breast cancer for white females who are being examined anually. J Natl Cancer Inst. 1998, 81: 1879-1886. 10.1093/jnci/81.24.1879.CrossRef Gail MH, Brinton LA, Byar DP, et al: Projecting individualized probabilities of developing breast cancer for white females who are being examined anually. J Natl Cancer Inst. 1998, 81: 1879-1886. 10.1093/jnci/81.24.1879.CrossRef
32.
go back to reference Claus EB, Risch N, Thompson D: Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer. 1994, 73: 643-651. 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5.CrossRefPubMed Claus EB, Risch N, Thompson D: Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer. 1994, 73: 643-651. 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5.CrossRefPubMed
33.
go back to reference Tyrer J, Duffy SW, Cuzick J: A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2005, 23: 1111-1130. 10.1002/sim.1668.CrossRef Tyrer J, Duffy SW, Cuzick J: A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2005, 23: 1111-1130. 10.1002/sim.1668.CrossRef
35.
go back to reference ASCO Subcommittee on Genetic Testing for Cancer Susceptibility: Statement of the American Society of Clinical Oncology: Genetic Testing for Cancer Susceptibility. J Clin Oncol. 2006, 14: 1730-1736. ASCO Subcommittee on Genetic Testing for Cancer Susceptibility: Statement of the American Society of Clinical Oncology: Genetic Testing for Cancer Susceptibility. J Clin Oncol. 2006, 14: 1730-1736.
38.
go back to reference Naseem H, Boylan J, Speake D, et al: Inherited association of breast and colorectal cancer: limited role of CHEK2 compared with high-penetrance genes. Clin Genet. 2006, 70: 388-395. 10.1111/j.1399-0004.2006.00698.x.CrossRefPubMed Naseem H, Boylan J, Speake D, et al: Inherited association of breast and colorectal cancer: limited role of CHEK2 compared with high-penetrance genes. Clin Genet. 2006, 70: 388-395. 10.1111/j.1399-0004.2006.00698.x.CrossRefPubMed
39.
go back to reference Penchaszadeh VB: Community genetics in Latin America: challenges and perspectives. Community Genet. 2000, 3: 124-127. 10.1159/000051121. Penchaszadeh VB: Community genetics in Latin America: challenges and perspectives. Community Genet. 2000, 3: 124-127. 10.1159/000051121.
40.
go back to reference Hughes KS, Roche C, Campbell CT, et al: Prevalence of family history of breast and ovarian cancer in a single primary care practice using a self-administered questionnaire. Breast J. 2003, 1: 19-25. 10.1046/j.1524-4741.2003.09105.x.CrossRef Hughes KS, Roche C, Campbell CT, et al: Prevalence of family history of breast and ovarian cancer in a single primary care practice using a self-administered questionnaire. Breast J. 2003, 1: 19-25. 10.1046/j.1524-4741.2003.09105.x.CrossRef
41.
go back to reference Hoskins KF, Zwaagstra A, Ranz M: Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening. Cancer. 2006, 107: 1769-1776. 10.1002/cncr.22202.CrossRefPubMed Hoskins KF, Zwaagstra A, Ranz M: Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening. Cancer. 2006, 107: 1769-1776. 10.1002/cncr.22202.CrossRefPubMed
42.
go back to reference Gonzalez KD, Noltner KA, Buzin CH, et al: Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009, 27: 1250-1256. 10.1200/JCO.2008.16.6959.CrossRefPubMed Gonzalez KD, Noltner KA, Buzin CH, et al: Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009, 27: 1250-1256. 10.1200/JCO.2008.16.6959.CrossRefPubMed
43.
go back to reference Weitzel JN, Lagos VI, Cullinane CA, et al: Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer. JAMA. 2007, 297: 2587-2595. 10.1001/jama.297.23.2587.CrossRefPubMed Weitzel JN, Lagos VI, Cullinane CA, et al: Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer. JAMA. 2007, 297: 2587-2595. 10.1001/jama.297.23.2587.CrossRefPubMed
Metadata
Title
Development and validation of a simple questionnaire for the identification of hereditary breast cancer in primary care
Authors
Patricia Ashton-Prolla
Juliana Giacomazzi
Aishameriane V Schmidt
Fernanda L Roth
Edenir I Palmero
Luciane Kalakun
Ernestina S Aguiar
Susana M Moreira
Erica Batassini
Vanessa Belo-Reyes
Lavinia Schuler-Faccini
Roberto Giugliani
Maira Caleffi
Suzi Alves Camey
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-283

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine